4-(2-吗啉-4-基-乙氧基)苯甲酸甲酯 | 92501-87-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-吗啉-4-基-乙氧基)苯甲酸甲酯
• 英文名称: methyl 4-(2-morpholinoethoxy)benzoate
• 英文别名: Methyl 4-(2-morpholin-4-YL-ethoxy)benzoate；methyl 4-(2-morpholin-4-ylethoxy)benzoate
• CAS: 92501-87-6
• 化学式: C₁₄H₁₉NO₄
• mdl: MFCD02931304
• 分子量: 265.309
• InChiKey: QNUQDDPNECMPAT-UHFFFAOYSA-N

物化性质

• 沸点：
  164 °C(Press: 0.5 Torr)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-吗啉-4-基-乙氧基)苯甲酸甲酯 在 氯化亚砜 、 sodium hydroxide 作用下， 生成 3,5-Dibenzylidene-1-[4-(2-morpholin-4-ylethoxy)benzoyl]piperidin-4-one
  参考文献：
  名称：

  3,5-Bis(benzylidene)-4-piperidones and related N-acyl analogs: A novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum

  摘要：

  Drug resistance is a major challenge in antimalarial chemotherapy. In addition, a complete cure of malaria requires intervention at various stages in the development of the parasite within the host. There are only a few antimalarials that target the liver stage of the Plasmodium species which is an essential part of the life cycle of the malarial parasite. We report a series of antimalarial 3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs 1-5, a number of which exhibit potent in vitro growth-inhibiting properties towards drug-sensitive D6 and drug-resistant C235 strains of Plasmodium falciparum as well as inhibiting the liver stage development of the malarial life cycle. The compounds 2b (IC50: 165 ng/mL), 3b (IC50: 186 ng/mL), 5c (IC50: 159 ng/mL) and 5d (IC50: 93.5 ng/mL) emerged as lead molecules that inhibit liver stage Plasmodium berghei and are significantly more potent than chloroquine (IC50: >2000 ng/mL) and mefloquine (IC50: >2000 ng/mL) in this screen. All the compounds that showed potent inhibitory activity against the P. berghei liver stage were nontoxic to human HepG2 liver cells (IC50: >2000 ng/mL). The compounds 5a and 5b exhibit comparable metabolic stability as chloroquine and mefloquine in human plasma and the most potent compound 5d demonstrated suitable permeability characteristics using the MDCK monolayer. These results emphasize the value of 3,5-bis(benzylidene)-4-piperidones as novel antimalarials for further drug development. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.09.065
• 作为产物：
  描述：

  对羟基苯甲酸甲酯 在 potassium carbonate 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 4.0h， 生成 4-(2-吗啉-4-基-乙氧基)苯甲酸甲酯
  参考文献：
  名称：

  高效治疗特发性肺纤维化的新型二芳基酰基腙衍生物的设计、合成及生物学评价

  摘要：

  特发性肺纤维化（IPF）是一种致命的肺部疾病，其特点是病死率高、病因不明且缺乏有效治疗。许多证据证实抑制 STAT3 的激活是一种有吸引力的 IPF 治疗策略。在此，基于我们之前发现的硝呋恶嗪 (NIF) 可以通过抑制 STAT3 激活有效减轻肺纤维化，我们设计并合成了一系列二芳基酰肼衍生物。其中，化合物44和52可抑制TGF-β1诱导的NIH-3T3和A549细胞的异常活化，以及A549细胞的迁移和EMT。在博来霉素诱导的小鼠肺纤维化模型中，口服给药44和52（生物利用度 F = 31.75% 和 42.08%）改善小鼠肺功能并减缓 IPF 的进展。此外，52可以逆转治疗模型中的肺纤维化。总的来说，这项工作表明44和52可能是治疗 IPF 的潜在先导化合物，值得进一步研究。

  DOI：

  10.1016/j.ejmech.2022.114918

文献信息

• [EN] USE OF AND SOME NOVEL IMIDAZOPYRIDINES<br/>[FR] NOUVELLES IMIDAZOPYRIDINES ET LEUR UTILISATION
  申请人：ASTRAZENECA AB

  公开号：WO2004016611A1

  公开（公告）日：2004-02-26

  The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compounds of formula (I), together with processes for their preparation, compositions containing them and their use in therapy are also disclosed.

  公开了在制备药物用于治疗或预防抑制激酶Itk活性有益的疾病或症状中，使用式(I)中R1、R3、R10、m和Ar所定义的化合物及其药学上可接受的盐。还公开了式(I)的某些新化合物，以及它们的制备方法、含有它们的组合物和它们在治疗中的用途。
• [EN] C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAU TRITERPÉNONE EN C-3 AVEC DES DÉRIVÉS D'AMIDE INVERSE EN C-17 EN TANT QU'INHIBITEURS DU VIH
  申请人：HETERO LABS LTD

  公开号：WO2018029604A1

  公开（公告）日：2018-02-15

  The present invention relates to C-3 novel triterpenone with C-17 reverse amide compounds of Formula (I); and pharmaceutically acceptable salts thereof, wherein ring Formula (II), R1, R2, R3, R4, R5, R6, R7, 'n' and 'm' are as defined in Formula (I). The invention also relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

  本发明涉及具有式（I）的C-17反酰胺化合物的C-3新型三萜酮，及其药学上可接受的盐，其中环式（II），R1、R2、R3、R4、R5、R6、R7，'n'和'm'如式（I）中所定义。该发明还涉及C-3新型三萜酮与C-17反酰胺衍生物、相关化合物和用于治疗病毒性疾病，特别是HIV介导疾病的药物组合物。
• [EN] OXABOROLE ESTERS AND USES THEREOF<br/>[FR] ESTERS D'OXABOROLE ET LEURS UTILISATIONS
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2017195069A1

  公开（公告）日：2017-11-16

  The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

  本发明提供了氧硼酯酯化合物及其组合物，可用于治疗与寄生虫相关的疾病，如充血性心脏病和非洲动物锥虫病。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2005030704A1

  公开（公告）日：2005-04-07

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  这项发明涉及抑制组蛋白去乙酰化酶。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了治疗细胞增殖性疾病和症状的组合物和方法。
• Falcipain Inhibitors: Optimization Studies of the 2-Pyrimidinecarbonitrile Lead Series
  作者：Jose M. Coterón、David Catterick、Julia Castro、María J. Chaparro、Beatriz Díaz、Esther Fernández、Santiago Ferrer、Francisco J. Gamo、Mariola Gordo、Jiri Gut、Laura de las Heras、Jennifer Legac、Maria Marco、Juan Miguel、Vicente Muñoz、Esther Porras、Juan C. de la Rosa、Jose R. Ruiz、Elena Sandoval、Pilar Ventosa、Philip J. Rosenthal、Jose M. Fiandor

  DOI：10.1021/jm100556b

  日期：2010.8.26

  were studied as potential falcipain inhibitors and therefore potential antiparasitic lead compounds, with the 5-substituted-2-cyanopyrimidine chemical class emerging as the most potent and promising lead series. Through a sequential lead optimization process considering the different positions present in the initial scaffold, nanomolar and subnanomolar inhibitors at falcipains 2 and 3 were identified

  Falcipain-2和falcipain-3是疟原虫恶性疟原虫的木瓜蛋白酶家族半胱氨酸蛋白酶负责宿主血红蛋白水解以提供用于寄生虫蛋白质合成的氨基酸。研究了不同的杂芳基腈衍生物作为潜在的falcipain抑制剂，因此潜在的抗寄生虫铅化合物，其中5-取代的2-氰基嘧啶化学类别成为最有效和有前途的铅系列。考虑到初始支架中存在的不同位置，通过顺序的前导优化过程，鉴定出了在恶性激素2和3处的纳摩尔和亚纳摩尔抑制剂，并具有在微摩尔范围内对抗培养的寄生虫的活性。在铅分子中引入质子化胺后，对培养的寄生虫的活性显着提高了1000倍，而其他SAR趋势没有明显改变。